Results from the HELP OLE study demonstrated that long-term treatment with lanadelumab may provide health-related quality of life (HRQoL) benefits in patients with hereditary angioedema (HAE), according to a study published in the Annals of Allergy, Asthma & Immunology.

To measure the impact of long-term lanadelumab treatment on patient-reported outcomes, the study authors gathered 109 rollover patients who had already completed the 26-week HELP study and 103 newly enrolled patients.

All participants received 300 mg of lanadelumab every 2 weeks. They also completed several questionnaires measuring patient-reported outcomes at baseline and various time points until the end of the study. The Angioedema Control Test, Treatment Satisfaction Questionnaire for Medication, and Global Impression of Treatment Response were also administered starting from week 52.


Continue Reading

According to the results, rollover patients demonstrated a mean change in Angioedema Quality of Life Questionnaire score of −10.2, indicating an improvement in HRQoL since participating in the HELP study. Moreover, 48.9% of these patients achieved the previously defined 6-point minimal clinically important difference.

Read more about HAE treatment

Newly enrolled patients with HAE reported a change of −19.5 in Angioedema Quality of Life Questionnaire score. Controlled disease, as evidenced by an Angioedema Control Test total score of at least 10, was reported by 90.2% of rollover patients and 95.9% of newly enrolled patients at the end of the study.

Furthermore, 78.7% of patients and 82.4% of investigators reported an excellent treatment response. There was a slight improvement in anxiety, a high level of satisfaction with treatment, and increased work productivity and activity.

“Management of HAE has shifted in recent years; although the focus remains on treating and reducing attacks, there is more attention on addressing the broader burden of HAE on patients’ lives and considering individual patient preferences when making treatment decisions,” Lumry and colleagues noted. “This emphasis on patient preference is supported by the development of a consensus statement and a regulatory initiative on the importance of understanding patients’ goals for treatment beyond the number of attacks.”

HAE is associated with a substantial disease burden both during and between attacks despite the use of available treatments. Most patients experience anxiety about future attacks, depression, decreased productivity at work and school, limitations in performing daily activities, and an overall negative effect on QoL.

Reference

Lumry WR, Maurer M, Weller K, et al; HELP OLE Study Group. Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema. Ann Allergy Asthma Immunol. Published online April 5, 2023. doi:10.1016/j.anai.2023.03.028